Browse TIPARP

Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00644 Poly(ADP-ribose) polymerase catalytic domain
Function

Poly [ADP-ribose] polymerase using NAD(+) as a substrate to transfer ADP-ribose onto glutamic acid residues of a protein acceptor; repeated rounds of ADP-ribosylation leads to the formation of poly(ADPribose) chains on the protein, thereby altering the function of the target protein. May play a role in the adaptive response to chemical exposure (TCDD) and thereby mediates certain effects of the chemicals (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001570 vasculogenesis
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0006471 protein ADP-ribosylation
GO:0006486 protein glycosylation
GO:0007548 sex differentiation
GO:0008209 androgen metabolic process
GO:0008210 estrogen metabolic process
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009791 post-embryonic development
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010171 body morphogenesis
GO:0010817 regulation of hormone levels
GO:0034754 cellular hormone metabolic process
GO:0042176 regulation of protein catabolic process
GO:0042445 hormone metabolic process
GO:0043413 macromolecule glycosylation
GO:0044236 multicellular organism metabolic process
GO:0045137 development of primary sexual characteristics
GO:0045732 positive regulation of protein catabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048008 platelet-derived growth factor receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048608 reproductive structure development
GO:0048705 skeletal system morphogenesis
GO:0048745 smooth muscle tissue development
GO:0060021 palate development
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060325 face morphogenesis
GO:0060537 muscle tissue development
GO:0061458 reproductive system development
GO:0070085 glycosylation
GO:0071407 cellular response to organic cyclic compound
GO:0072001 renal system development
Molecular Function GO:0003950 NAD+ ADP-ribosyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016763 transferase activity, transferring pentosyl groups
GO:0035326 enhancer binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TIPARP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TIPARP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.18; FDR: 0.00700 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TIPARP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3280.234
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1770.892
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4460.607
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0720.903
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5270.806
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8310.762
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1150.75
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0990.943
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3530.819
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0340.968
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8410.51
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0550.6
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TIPARP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TIPARP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TIPARP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TIPARP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TIPARP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TIPARP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TIPARP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTIPARP
NameTCDD-inducible poly(ADP-ribose) polymerase
Aliases DKFZP434J214; DKFZp686N0351; DDF1; PARP7; PARP-7; pART14; RM1; ARTD14; ADP-ribosyltransferase diphtheria tox ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TIPARP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.